Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on invested capital (ROIC) is -16.54% as of the fiscal period ended Tuesday, June 30, 2026.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation.
Limited quarterly history available
ROIC needs at least three reported quarters before a meaningful chart is shown.
RETURN ON INVESTED CAPITAL (ROIC)
-16.54%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-28.69%
median of 497 covered companies
CURRENT VS SECTOR MEDIAN
+42.33%
vs the sector median at left
Aktis Oncology, Inc.
Market Cap
$995.46M
Return on Invested Capital (ROIC)
-16.54%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.01B
Return on Invested Capital (ROIC)
-28.14%
TTM Avg
-132.46%
3Y Avg
-76.17%
5Y Avg
-76.17%
Market Cap
$1.02B
Return on Invested Capital (ROIC)
-15.15%
TTM Avg
-12.74%
3Y Avg
-16.16%
5Y Avg
-18.46%
Market Cap
$954.32M
Return on Invested Capital (ROIC)
-67.13%
TTM Avg
-38.55%
3Y Avg
-37.38%
5Y Avg
-31.65%
Market Cap
$1.04B
Return on Invested Capital (ROIC)
-53.36%
TTM Avg
-19.72%
3Y Avg
-15.42%
5Y Avg
-34.93%
Market Cap
$946.67M
Return on Invested Capital (ROIC)
-46.54%
TTM Avg
-25.88%
3Y Avg
-39.60%
5Y Avg
-39.60%
Market Cap
$1.05B
Return on Invested Capital (ROIC)
20.01%
TTM Avg
1.42%
3Y Avg
2.77%
5Y Avg
3.34%
Market Cap
$1.05B
Return on Invested Capital (ROIC)
0.86%
TTM Avg
2.66%
3Y Avg
2.26%
5Y Avg
2.26%
Market Cap
$1.06B
Return on Invested Capital (ROIC)
-7.32%
TTM Avg
-21.18%
3Y Avg
-91.27%
5Y Avg
-61.58%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aktis Oncology, Inc. (AKTS) | $995.46M | -16.54% | N/A | N/A | N/A |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $1.01B | -28.14% | -132.46% | -76.17% | -76.17% |
| Janux Therapeutics, Inc. (JANX)vs › | $1.02B | -15.15% | -12.74% | -16.16% | -18.46% |
| Kura Oncology, Inc. (KURA)vs › | $954.32M | -67.13% | -38.55% | -37.38% | -31.65% |
| Immatics N.V. (IMTX)vs › | $1.04B | -53.36% | -19.72% | -15.42% | -34.93% |
| CeriBell, Inc. (CBLL)vs › | $946.67M | -46.54% | -25.88% | -39.60% | -39.60% |
| Integra LifeSciences Holdings Corporation (IART)vs › | $1.05B | 20.01% | 1.42% | 2.77% | 3.34% |
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI)vs › | $1.05B | 0.86% | 2.66% | 2.26% | 2.26% |
| Teladoc Health, Inc. (TDOC)vs › | $1.06B | -7.32% | -21.18% | -91.27% | -61.58% |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $1.06B | -68.64% | -46.08% | -28.67% | -26.80% |
ROIC
-16.5%
ROE
-15.1%
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-06-30 | -16.54% |
